Spots Global Cancer Trial Database for histopathological response
Every month we try and update this database with for histopathological response cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. | NCT03773367 | Resectable Gast... | Fluorouracil Oxaliplatin Irinotecan | 18 Years - | Lund University Hospital | |
Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer | NCT02591667 | Colorectal Canc... Peritoneal Meta... | Upfront staging... Neoadjuvant che... Surgical re-exp... | 18 Years - | Medical University of Vienna | |
Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer | NCT02591667 | Colorectal Canc... Peritoneal Meta... | Upfront staging... Neoadjuvant che... Surgical re-exp... | 18 Years - | Medical University of Vienna | |
Clinical Evaluation of Neoadjuvant Chemotherapy for Primary Malignant Sarcomas That Originate in Bone | NCT03742063 | Clinical Respon... Histopathologic... Prognosis | first-line chem... | - | Peking University People's Hospital | |
Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. | NCT03773367 | Resectable Gast... | Fluorouracil Oxaliplatin Irinotecan | 18 Years - | Lund University Hospital |